Dynavax

$16.34 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Dynavax

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Stock Analysis

last close $16.34
1-mo return 12.1%
3-mo return 106.2%
avg daily vol. 2.23M
52-week high 21.39
52-week low 7.26
market cap. $2.1B
forward pe 81.7
annual div. -
roe 90.2%
ltg forecast -
dividend yield -
annual rev. $674M
inst own. 85.6%
baraka

Subscribe now for daily local and international financial news

Subscribe